Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Treatment and Sequencing Strategies: Providing the Best Care for Patients with Metastatic Urothelial Carcinoma (mUC)

Premiere Date: Friday, February 26, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, February 26, 2022
Note: Credit Is No Longer Available


Daniel P. Petrylak, MDDaniel P. Petrylak, MD 
Professor of Medicine (Medical Oncology) and Urology
Yale School of Medicine
Co-Director, Signal Transduction Research Program
Smilow Cancer Center
New Haven, CT

Guru Sonpavde, MDGuru Sonpavde, MD 
Bladder Cancer Director
Dana Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Statement of Need

The need for second-line (2L) treatment strategies in locally advanced and metastatic UC (mUC) is imperative, as most patients will have disease progression within ~9 months of first-line (1L) therapies. Clinical management is challenged by heterogeneous patient populations, which underscores the need to optimize 2L treatments that yield durable response.

This CMEOCast podcast features expert faculty evaluating efficacy data for 1L and 2L sequencing strategies in patients with mUC highighting immune checkpoint inhibitors and other novel agents, as well as provide strategies for managing adverse events during treatment.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Utilize upfront treatment and sequencing strategies in MUC immunotherapy to provide the best care with 2L treatment options.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Identify upfront treatment and sequencing strategies in MUC immunotherapy used to provide the best care with 2L treatment options.

Financial Support

Supported by an educational grant from Pfizer Inc. and EMD Serono, Inc.

Target Audience

Oncologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.005 CEUs) Universal Activity Number:
Enduring: 0376-0000-21-068-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Petrylak reports that he receives grants from Ada Cap (Advanced Accelerator Applications); Agensys, Inc.; * Astellas Pharma US, Inc.; AstraZeneca; *Bayer; BioXcel Therapeutics, Inc.; Bristol-Myers Squibb Company; Clovis Oncology; Eisai Inc.; * Eli Lilly and Company; *Endocyte; Genentech, Inc.; * Innocrin Pharmaceuticals Inc.; MedImmune, Inc.; Medivation, Inc.; Merck & Co.; Mirati Therapeutics, Inc.; *Novarti; Pfizer Inc.; * Progenics Pharmaceuticals Inc.; Replimune Group Inc; Roche; *Sanofi-Aventis; and Seattle Genetics. He is a consultant for AdaCap (Advanced Accelerator Applications); Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb Company; Clovis Oncology; Eli Lilly and Company; Exelixis, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Monopteros Therapeutics, Inc.; Pfizer Inc.; Pharmacyclics; Roche; Seattle Genetics and UroGen Pharma, Inc. He held ownership interest/investmetns in Bellicum Pharmaceuticals, Inc. (sold 7/2020) and Tyme, Inc. (sold 10/2019).
*Denotes study trials that have terminated

Dr. Sonpavde reports that he receives research support from AstraZeneca; Immunomedics; QED Therapeutics, Inc.; and Sanofi. He is a consultant for AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb Company; EMD Serono, Inc.; Exelixis, Inc.; Genentech, Inc.; Immunomedics; Janssen Pharmaceuticals, Inc.; Merck & Co.; Pfizer Inc.; Sanofi; and Seattle Genetics/Astellas Pharma US, Inc. He receives other financial or material support from AstraZeneca; Bladder Cancer Center of Excellence Steering Committee; Bristol-Myers Squibb Company; Debiopharm; Editor of Elsevier Practice Update; EMD Serono, Inc.; QED Therapeutics, Inc.; Seattle Genetics; and UpToDate, Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report

Mae Ochoa, RPh (peer reviewer) has no disclosures to report

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download